Resection of Solid Tumors Reverses T Cell Defects and Restores Protective Immunity
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
We have previously reported that CTL were demonstrable early after inoculation of CMS5 fibrosarcoma cells, but that they disappeared within 3 wk. These mice were unable to reject a challenge with CMS5 tumor cells. Other studies demonstrated cell surface phenotype and signaling abnormalities of cells within the spleen. Since we assumed that such an environment would make it more difficult to elicit antitumor immune responses via immunotherapy, we asked whether resection of the tumor could reverse these abnormalities. Although early after tumor cell inoculation tumor resection leads to the development of immunity, the effect at late time points has not been studied critically. To test this, mice were inoculated s.c. with CMS5 cells and after 28 days the tumors were resected. We observed a gradual normalization of the cellular phenotype of the spleen. In particular, there was a decrease in the number of Mac1+/Gr1high cells and an increase in the number of CD3+ cells in the spleen within 24–48 h of tumor resection. By day 10, these values were normal. Levels of p56lck increased as well. The functional implications of these changes were illustrated by the reduced growth rate or the complete rejection of a challenge of tumor cells in the resected mice. Both CD4+ and CD8+ cells were involved in the restoration of tumor immunity. Our results suggested that tumor resection not only led to the reversal of immune suppression, but also unmasked a population of primed T cells able to mediate protective immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., & Linsley, P. S. (1992) · Cell · doi:10.1016/s0092-8674(05)80059-5 · Cited by 1,050 · cited 1×
“Several mechanisms have been proposed to explain the failure of the immune response to contain tumor growth, including poor Ag-presenting ability of tumor cells (26, 27), the induction of peripheral tolerance or anergy to tumor cells that fail to deliver costimulatory signals (26–29), the emergence of Ag loss variants…”
Background
Cited by
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054
Mechanisms and functional significance of tumour-induced dendritic-cell defects
Gabrilovich, D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1498 · Cited by 1,024
Dynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990
“vascular endothelial growth factor, and granulocyte macrophage colony-stimulating factor (45), and removal of the primary tumor results in a decrease of MDSC and restores T-cell function (46).”
BackgroundKusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 850
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
Gallina, G., Dolcetti, L., Serafini, P., Santo, C. D., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28828 · Cited by 792
SERAFINI, P., BORRELLO, I., & BRONTE, V (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.005 · Cited by 762
Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism
Mazzoni, A., Bronte, V., Visintin, A., Spitzer, J. H., Apolloni, E., Serafini, P., Zanovello, P., & Segal, D. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.689 · Cited by 690
Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells
Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., & Bronte, V. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00602.x · Cited by 608
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S., Pratt, B., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 539
IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice
Bronte, V., Serafini, P., De Santo, C., Marigo, I., Tosello, V., Mazzoni, A., Segal, D. M., Staib, C., Lowel, M., Sutter, G., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.270 · Cited by 513
Popovic, P. J., Zeh, H. J., & Ochoa, J. B. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.6.1681s · Cited by 391
Danna, E. A., Sinha, P., Gilbert, M., Clements, V. K., Pulaski, B. A., & Ostrand-Rosenberg, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2646 · Cited by 371
Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer
Kusmartsev, S., & Gabrilovich, D. I. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0048-z · Cited by 346
Derangement of immune responses by myeloid suppressor cells
Serafini, P., De Santo, C., Marigo, I., Cingarlini, S., Dolcetti, L., Gallina, G., Zanovello, P., & Bronte, V. (2004) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0443-2 · Cited by 335
Keilholz, U., Weber, J., Finke, J. H., Gabrilovich, D. I., Kast, W. M., Disis, M. L., Kirkwood, J. M., Scheibenbogen, C., Schlom, J., Maino, V. C., et al. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200203000-00001 · Cited by 298
Immature myeloid cells and cancer-associated immune suppression
Kusmartsev, S., & Gabrilovich, D. I. (2002) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-002-0280-8 · Cited by 297
Melani, C., Chiodoni, C., Forni, G., & Colombo, M. P. (2003) · Blood · doi:10.1182/blood-2003-01-0190 · Cited by 295
Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species
Kusmartsev, S., & Gabrilovich, D. I. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0103010 · Cited by 292
Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C. A., Voronov, E., & Apte, R. N. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.8200 · Cited by 290
Tumor-Induced Immune Dysfunctions Caused by Myeloid Suppressor Cells
Bronte, V., Serafini, P., Apolloni, E., & Zanovello, P. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200111000-00001 · Cited by 250
“The resection of a primary mouse fibrosarcoma was sufficient to normalize the number of Gr-1/CD11b MSCs, correct the p56 abnormalities in T lymphocytes, and restore tumor immunity because the resected mice were able to reject a second challenge of the same tumor, an interesting example of concomitant immunity (47).”
BackgroundDerhovanessian, E., Solana, R., Larbi, A., & Pawelec, G. (2008) · Immunity & Ageing · doi:10.1186/1742-4933-5-11 · Cited by 169
“The presence of cancer is commonly associated with compromised immune responses [95]; surgical removal of the tumour can result in restoration of immunity [151].”
BackgroundTerrazas, L. I., Walsh, K. L., Piskorska, D., McGuire, E., & Harn, D. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.5294 · Cited by 169
Suzuki, E., Kim, S., Cheung, H.-K., Corbley, M. J., Zhang, X., Sun, L., Shan, F., Singh, J., Lee, W.-C., Albelda, S. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2389 · Cited by 113
Friedman, J., Moore, E. C., Zolkind, P., Robbins, Y., Clavijo, P. E., Sun, L., Greene, S., Morisada, M. V., Mydlarz, W. K., Schmitt, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2209 · Cited by 88
Metadata
- Authors
- Salvadori, S., Martinelli, G., & Zier, K.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-02
- Volume
- 164
- Issue
- 4
- Pages
- 2214-2220
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2169417547
- Cited by
- 142
- References
- 2
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.